Influence of Alpha-2-Macroglobulin 5 bp I/D and Ile1000Val Polymorphisms on the Susceptibility of Alzheimer's disease: A Systematic Review and Meta-analysis of 52 Studies

Cell Biochemistry and Biophysics

Volumn 70, Issue 1, 2014, Pages 511-519

  Chen, Hui ^a   Li, Zhongxuan ^b   liu, Nan ^a   Zhang, Weiwei ^a   Zhu, Guangming ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

A2M; Alpha 2 macroglobulin; Meta analysis; Polymorphism

Indexed keywords

ALPHA 2 MACROGLOBULIN;

ALZHEIMER DISEASE; GENETIC PREDISPOSITION; GENETICS; HUMAN; INDEL MUTATION; META ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ALPHA-MACROGLOBULINS; ALZHEIMER DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDEL MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84906272761     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-9950-3     Document Type: Article

References (72)

1. Hughes, S. R., et al. (1998). Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proceedings of National Academy of Sciences U S A, 95(6), 3275-3280.
2. Matthijs, G., & Marynen, P. (1991). A deletion polymorphism in the human alpha-2-macroglobulin (A2 M) gene. Nucleic Acids Research, 19(18), 5102.
3. Poller, W., Faber, J. P., & Olek, K. (1991). Sequence polymorphism in the human alpha-2-macroglobulin (A2 M) gene. Nucleic Acids Research, 19(1), 198.
4. Koster, M. N., et al. (2000). The alpha2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology, 55(5), 678-684.
5. Xu, X., et al. (2013). Meta-analyses of 8 polymorphisms associated with the risk of the Alzheimer's disease. PLoS ONE, 8(9), e73129.
6. Mantel, N., & Haenszel, W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute, 22(4), 719-748.
7. DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177-188.
8. Yuan, Q., et al. (2013). Association of polymorphisms in the LRP1 and A2 M genes with Alzheimer's disease in the Northern Chinese Han population. Journal of Clinical Neurosciences, 20(2), 253-256.
9. Bruno, E., et al. (2010). Lack of interaction between LRP1 and A2 M polymorphisms for the risk of Alzheimer disease. Neuroscience Letters, 482(2), 112-116.
10. Colacicco, A. M., et al. (2009). Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease. Neurobiology of Aging, 30(9), 1518-1520.
11. Mariani, E., et al. (2006). Interaction of CTSD and A2 M polymorphisms in the risk for Alzheimer's disease. Journal of the Neurological Sciences, 247(2), 187-191.
12. Depboylu, C., et al. (2006). Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's disease. Neuroscience Letters, 400(3), 187-190.
13. Sun, Y., et al. (2005). No evidence for genetic association between alpha-2 macroglobulin I1000 V polymorphism and sporadic Alzheimer's disease in two independent Chinese populations. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 22(2), 174-179.
14. Bian, L., et al. (2005). Association study of the A2 M and LRP1 Genes with Alzheimer disease in the Han Chinese. Biological Psychiatry, 58(9), 731-737.
15. Zappia, M., et al. (2004). Increased risk for Alzheimer disease with the interaction of MPO and A2 M polymorphisms. Archives of Neurology, 61(3), 341-344.
16. Chen, D., et al. (2004). Association of alpha 2-macroglobulin polymorphisms and Alzheimer disease in Mainland Han Chinese. Journal of the Neurological Sciences, 217(1), 13-15.
17. Styczynska, M., et al. (2003). Simultaneous analysis of five genetic risk factors in Polish patients with Alzheimer's disease. Neuroscience Letters, 344(2), 99-102.
18. Clarimon, J., et al. (2003). Joint analysis of candidate genes related to Alzheimer's disease in a Spanish population. Psychiatric Genetics, 13(2), 85-90.
19. Zappia, M., et al. (2002). Genetic association of alpha2-macroglobulin polymorphisms with AD in southern Italy. Neurology, 59(5), 756-758.
20. Tang, G., et al. (2002). Alpha-2 macroglobulin I1000 V polymorphism in Chinese sporadic Alzheimer's disease and Parkinson's disease. Neuroscience Letters, 328(2), 195-197.
21. Poduslo, S. E., et al. (2002). Lack of association of the two polymorphisms in alpha-2 macroglobulin with Alzheimer disease. American Journal of Medical Genetics, 110(1), 30-35.
22. Janka, Z., et al. (2002). Alpha2-macroglobulin exon 24 (Val-1000-Ile) polymorphism is not associated with late-onset sporadic Alzheimer's dementia in the Hungarian population. Psychiatric Genetics, 12(1), 49-54.
23. Wang, X., et al. (2001). Lack of association between alpha2-macroglobulin polymorphisms and Alzheimer's disease. Human Genetics, 108(2), 105-108.
24. Nacmias, B., et al. (2001). Alpha2-macroglobulin polymorphisms in Italian sporadic and familial Alzheimer's disease. Neuroscience Letters, 299(1-2), 9-12.
25. McIlroy, S. P., et al. (2001). Common polymorphisms in LRP and A2 M do not affect genetic risk for Alzheimer disease in Northern Ireland. American Journal of Medical Genetics, 105(6), 502-506.
26. Zill, P., et al. (2000). Polymorphisms in the alpha-2 macroglobulin gene in psychogeriatric patients. Neuroscience Letters, 294(2), 69-72.
27. Shibata, N., et al. (2000). No genetic association between alpha-2 macroglobulin I1000 V polymorphism and Japanese sporadic Alzheimer's disease. Neuroscience Letters, 290(2), 154-156.
28. Romas, S. N., et al. (2000). The deletion polymorphism and Val1000Ile in alpha-2-macroglobulin and Alzheimer disease in Caribbean Hispanics. Neuroscience Letters, 279(3), 133-136.
29. Hu, C. J., et al. (2000). Genetic risk factors of sporadic Alzheimer's disease among Chinese in Taiwan. Journal of the Neurological Sciences, 181(1-2), 127-131.
30. Higuchi, S., et al. (2000). Alpha2-macroglobulin gene polymorphisms show racial diversity and are not associated with Alzheimer's disease. NeuroReport, 11(6), 1167-1171.
31. Gibson, A. M., et al. (2000). Lack of association of the alpha2-macroglobulin locus on chromosome 12 in AD. Neurology, 54(2), 433-438.
32. Wavrant-DeVrieze, F., et al. (1999). No association between the alpha-2 macroglobulin I1000 V polymorphism and Alzheimer's disease. Neuroscience Letters, 262(2), 137-139.
33. Singleton, A. B., et al. (1999). Alpha2-macroglobulin polymorphisms in Alzheimer's disease and dementia with Lewy bodies. NeuroReport, 10(7), 1507-1510.
34. Myllykangas, L., et al. (1999). Genetic association of alpha2-macroglobulin with Alzheimer's disease in a Finnish elderly population. Annals of Neurology, 46(3), 382-390.
35. Liao, A., et al. (1998). Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Human Molecular Genetics, 7(12), 1953-1956.
36. Cai, L., et al. (2005). Genetic studies of A2 M and BACE1 genes in Chinese Han Alzheimer's disease patients. NeuroReport, 16(9), 1023-1026.
37. Zhang, P., et al. (2004). Neither the tumor necrosis factor alpha-308 A/G polymorphism nor the alpha2-macroglobulin polymorphism was associated with late-onset Alzheimer's disease in the Chinese population. Yi Chuan Xue Bao, 31(1), 1-6.
38. Camelo, D., et al. (2004). Angiotensin-converting enzyme and alpha-2-macroglobulin gene polymorphisms are not associated with Alzheimer's disease in Colombian patients. Journal of the Neurological Sciences, 218(1-2), 47-51.
39. Scacchi, R., et al. (2002). Alpha2-macroglobulin deletion polymorphism and plasma levels in late onset Alzheimer's disease. Clinical Chemistry and Laboratory Medicine, 40(4), 333-336.
40. Shi, J., et al. (2001). No evidence for association between the alpha 2-macroglobulin polymorphism and Alzheimer's disease in the Han Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 18(4), 299-302.
41. Prince, J. A., et al. (2001). Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. European Journal of Human Genetics, 9(6), 437-444.
42. Perry, R. T., et al. (2001). Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. American Journal of Medical Genetics, 105(4), 332-342.
43. Nicosia, F., et al. (2001). Analysis of alpha-2-macroglobulin-2 allele as a risk factor in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 12(5), 305-308.
44. Ki, C. S., et al. (2001). Alpha-1 antichymotrypsin and alpha-2 macroglobulin gene polymorphisms are not associated with Korean late-onset Alzheimer's disease. Neuroscience Letters, 302(2-3), 69-72.
45. Jhoo, J. H., et al. (2001). Association of alpha-2-macroglobulin deletion polymorphism with sporadic Alzheimer's disease in Koreans. Journal of the Neurological Sciences, 184(1), 21-25.
46. Sodeyama, N., et al. (2000). Alpha2-macroglobulin polymorphism is not associated with AD or AD-type neuropathology in the Japanese. Neurology, 54(2), 443-446.
47. Halimi, G., et al. (2000). Association of APOE promoter but not A2 M polymorphisms with risk of developing Alzheimer's disease. NeuroReport, 11(16), 3599-3601.
48. Dodel, R. C., et al. (2000). Alpha2 macroglobulin and the risk of Alzheimer's disease. Neurology, 54(2), 438-442.
49. Bullido, M. J., et al. (2000). Alzheimer's risk associated with human apolipoprotein E, alpha-2 macroglobulin and lipoprotein receptor related protein polymorphisms: absence of genetic interactions, and modulation by gender. Neuroscience Letters, 289(3), 213-216.
50. Blennow, K., et al. (2000). No association between the alpha2-macroglobulin (A2 M) deletion and Alzheimer's disease, and no change in A2 M mRNA, protein, or protein expression. Journal of Neural Transmission, 107(8-9), 1065-1079.
51. Bagli, M., et al. (2000). Identical distribution of the alpha 2-macroglobulin pentanucleotide deletion in subjects with Alzheimer disease and controls in a German population. American Journal of Medical Genetics, 96(6), 775-777.
52. Yamada, M., et al. (1999). A deletion polymorphism of alpha(2)-macroglobulin gene and cerebral amyloid angiopathy. Stroke, 30(11), 2277-2279.
53. Shibata, N., et al. (1999). Genetic association between alpha-2 macroglobulin and Japanese sporadic Alzheimer's disease. Neuroscience Letters, 271(2), 132-134.
54. Rudrasingham, V., et al. (1999). Alpha-2 macroglobulin gene and Alzheimer disease. Nat Genet, 22(1), 17-19. author reply 21-2.
55. Rogaeva, E. A., et al. (1999). An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nature Genetics, 22(1), 19-22.
56. Kovacs, T., Cairns, N. J., & Lantos, P. L. (1999). Alpha-2-macroglobulin intronic polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease. Neuroscience Letters, 273(1), 61-83.
57. Korovaitseva, G. I., et al. (1999). Alpha-2 macroglobulin gene in early- and late-onset Alzheimer disease. Neuroscience Letters, 271(2), 129-131.
58. Hu, C. J., et al. (1999). No association of alpha-2 macroglobulin gene five-nucleotide deletion with AD in Taiwan Chinese. Neurology, 53(3), 642-643.
59. Dow, D. J., et al. (1999). Alpha-2 macroglobulin polymorphism and Alzheimer disease risk in the UK. Nature Genetics, 22(1), 16-17. author reply 21-2.
60. Crawford, F., et al. (1999). The alpha-2 macroglobulin gene is not associated with Alzheimer's disease in a case-control sample. Neuroscience Letters, 270(3), 133-136.
61. Chen, L., et al. (1999). Apolipoprotein E promoter and alpha2-macroglobulin polymorphisms are not genetically associated with Chinese late onset Alzheimer's disease. Neuroscience Letters, 269(3), 173-177.
62. Alvarez, V., et al. (1999). Association between an alpha(2) macroglobulin DNA polymorphism and late-onset Alzheimer's disease. Biochemical and Biophysical Research Communications, 264(1), 48-50.
63. Blacker, D., et al. (1998). Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nature Genetics, 19(4), 357-360.
64. Pericak-Vance, M. A., et al. (1998). Complete genomic screen in late-onset familial Alzheimer's disease. Neurobiology of Aging, 19(1 Suppl), S39-S42.
65. Rehman, A. A., Ahsan, H., & Khan, F. H. (2013). alpha-2-Macroglobulin: a physiological guardian. Journal of Cellular Physiology, 228(8), 1665-1675.
66. Yerbury, J. J., & Wilson, M. R. (2010). Extracellular chaperones modulate the effects of Alzheimer's patient cerebrospinal fluid on Abeta(1-42) toxicity and uptake. Cell Stress Chaperones, 15(1), 115-121.
67. Licastro, F., et al. (1995). Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Disease and Associated Disorders, 9(2), 112-118.
68. Akuffo, E. L., et al. (2008). The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers, 13(6), 618-636.
69. Giometto, B., et al. (1988). Acute-phase proteins in Alzheimer's disease. European Neurology, 28(1), 30-33.
70. Rhinn, H., et al. (2013). Integrative genomics identifies APOE epsilon4 effectors in Alzheimer's disease. Nature, 500(7460), 45-50.
71. van Duijn, C. M., et al. (1994). Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nature Genetics, 7(1), 74-78.
72. Panza, F., et al. (2006). Candidate genes for late-onset Alzheimer's disease: focus on chromosome 12. Mechanisms of Ageing and Development, 127(1), 36-47.